Envudeucitinib vs zasocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Envudeucitinib

Developed by Alumis and partners

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06586112 · Phase 3 · completed

Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05739435 (registry estimate)

Reported efficacy

To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)

Result source: NCT06586112

zasocitinib

Developed by Takeda Pharmaceutical Company

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06108544 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07752108 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)

Result source: NCT06973291

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnvudeucitinibzasocitinib
PASI 7556.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
67.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043
PASI 90—Not posted · NCT0658873846.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
PASI 100—Not posted · NCT0658873832.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
sPGA 0/153.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
51.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043
DLQI, change—Not posted · NCT06588738-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839

PASI 75

Envudeucitinib
56.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
zasocitinib
67.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043

PASI 90

Envudeucitinib
—Not posted · NCT06588738
zasocitinib
46.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

PASI 100

Envudeucitinib
—Not posted · NCT06588738
zasocitinib
32.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

sPGA 0/1

Envudeucitinib
53.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
zasocitinib
51.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043

DLQI, change

Envudeucitinib
—Not posted · NCT06588738
zasocitinib
-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Envudeucitinib: 4 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnvudeucitinibzasocitinib
Dropout rate
10.3%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
15.4%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.5%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
16.7%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
9.6%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
13.2%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
13.5%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
16%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.6%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
5.6%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
1.9%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
1.9%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
2%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Serious AEs
0%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.7%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
2.8%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40mg BIDa
headache 7.7% (placebo 5.3%)
nasopharyngitis 7.7% (placebo 7.9%)
upper respiratory tract infection 7.7% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
40mg QD
headache 10.3% (placebo 5.3%)
acne 5.1% (placebo 0%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg BID
headache 7.7% (placebo 5.3%)
cough 5.1% (placebo 0%)
diarrhea 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg QD
headache 5.6% (placebo 5.3%)
upper respiratory tract infection 5.6% (placebo 0%)
acne 0% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
10mg QD
diabetes mellitus 5.6% (placebo 0%)
nasopharyngitis 5.6% (placebo 7.9%)
upper respiratory tract infection 5.6% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
30 mga
covid-19 13.5% (placebo 1.9%)
blood creatine phosphokinase increased 5.8% (placebo 3.8%)
dermatitis acneiform 5.8% (placebo 0%)
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
15 mg
covid-19 11.3% (placebo 1.9%)
acne 5.7% (placebo 0%)
blood creatine phosphokinase increased 5.7% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
5 mg
covid-19 7.7% (placebo 1.9%)
lymphocyte count decreased 5.8% (placebo 0%)
blood creatine phosphokinase increased 3.8% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
2 mg
covid-19 12% (placebo 1.9%)
alanine aminotransferase increased 6% (placebo 0%)
diarrhoea 6% (placebo 1.9%)
NCT04999839 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

zasocitinib

PASI 90 46.2% (n=52) vs 0% (n=52) placebo @ 12wk30 mg
responder rate · % of participants
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
45.3% (n=53) vs 0% (n=52) placebo @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
21.2% (n=52) vs 0% (n=52) placebo @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
8% (n=50) vs 0% (n=52) placebo @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
PASI 100 32.7% (n=52) vs 0% (n=52) placebo @ 12wk30 mg
responder rate · % of participants
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
15.1% (n=53) vs 0% (n=52) placebo @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
9.6% (n=52) vs 0% (n=52) placebo @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
2% (n=50) vs 0% (n=52) placebo @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
DLQI -8.9 vs -4.9 placebo score @ 12wk30 mg
absolute change · score
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
-8.5 vs -4.9 placebo score @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
-7.9 vs -4.9 placebo score @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
-5.3 vs -4.9 placebo score @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envudeucitinib's landscape · zasocitinib's landscape